Zheyu Li, Wenbo Ma, Linghui Gu, Jiayuan Xie, Kui Yang, Shibo Lin
{"title":"Recent developments in the utilization of pyridones as privileged scaffolds in drug discovery.","authors":"Zheyu Li, Wenbo Ma, Linghui Gu, Jiayuan Xie, Kui Yang, Shibo Lin","doi":"10.1080/17460441.2025.2507377","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Pyridones are six-membered, nitrogen-containing heterocycles, possessing two isomeric forms; these are 2-pyridones and 4-pyridones. Both pyridone rings display unique physicochemical properties including weak alkalinity and dual hydrogen-bond donor/acceptor propensities. These heterocyclic compounds are particularly underlined for their diverse biological effects, including their cytotoxicity activity as well as their antibacterial, antiviral, anti-inflammatory, and anti-fibrotic properties. This versatility has attracted remarkable interest and held promise for addressing the challenges of drug resistance.</p><p><strong>Area covered: </strong>This review is the outcome of literature searches conducted on articles published between 2022 and 2025 across several major databases, including PubMed, Scopus, and Web of Science, using specific keywords concerning 'pyridone' and 'bioactivity.' It focuses on the identification of therapeutic targets, the process of molecular mechanisms, and the plausible modes of interaction and binding.</p><p><strong>Expert opinion: </strong>Pyridones have been reported to exhibit a wide range of bioactivities by regulating critical signaling pathways that have a diverse influence on downstream gene expression, intracellular enzyme activity and cytoskeletal configuration. They are consequently used as privileged fragments in the design of biologically active molecules with promising application value in pharmaceutical chemistry. Further investigation will be required to enhance drug-like properties. Continuous progress in structure optimization and clinical trial results will help to provide a guideline for future drug candidate discovery.</p>","PeriodicalId":12267,"journal":{"name":"Expert Opinion on Drug Discovery","volume":" ","pages":"873-889"},"PeriodicalIF":6.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17460441.2025.2507377","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Pyridones are six-membered, nitrogen-containing heterocycles, possessing two isomeric forms; these are 2-pyridones and 4-pyridones. Both pyridone rings display unique physicochemical properties including weak alkalinity and dual hydrogen-bond donor/acceptor propensities. These heterocyclic compounds are particularly underlined for their diverse biological effects, including their cytotoxicity activity as well as their antibacterial, antiviral, anti-inflammatory, and anti-fibrotic properties. This versatility has attracted remarkable interest and held promise for addressing the challenges of drug resistance.
Area covered: This review is the outcome of literature searches conducted on articles published between 2022 and 2025 across several major databases, including PubMed, Scopus, and Web of Science, using specific keywords concerning 'pyridone' and 'bioactivity.' It focuses on the identification of therapeutic targets, the process of molecular mechanisms, and the plausible modes of interaction and binding.
Expert opinion: Pyridones have been reported to exhibit a wide range of bioactivities by regulating critical signaling pathways that have a diverse influence on downstream gene expression, intracellular enzyme activity and cytoskeletal configuration. They are consequently used as privileged fragments in the design of biologically active molecules with promising application value in pharmaceutical chemistry. Further investigation will be required to enhance drug-like properties. Continuous progress in structure optimization and clinical trial results will help to provide a guideline for future drug candidate discovery.
吡啶酮是六元含氮杂环化合物,具有两种异构体形式;这是2-吡啶酮和4-吡啶酮。两种吡啶酮环均表现出弱碱性和双氢键供体/受体倾向等独特的物理化学性质。这些杂环化合物因其不同的生物效应而受到特别强调,包括它们的细胞毒性活性以及它们的抗菌、抗病毒、抗炎和抗纤维化特性。这种多功能性引起了人们的极大兴趣,并为解决耐药性挑战带来了希望。涵盖领域:本综述是对几个主要数据库(包括PubMed、Scopus和Web of Science)在2022年至2025年间发表的文章进行文献检索的结果,其中使用了有关“吡啶酮”和“生物活性”的特定关键词。它着重于治疗靶点的识别,分子机制的过程,以及相互作用和结合的合理模式。专家意见:据报道,吡啶酮通过调节对下游基因表达、细胞内酶活性和细胞骨架结构有多种影响的关键信号通路,表现出广泛的生物活性。因此,它们被用作设计生物活性分子的特权片段,在药物化学中具有广阔的应用价值。需要进一步的研究来增强类似药物的特性。结构优化和临床试验结果的不断进展将有助于为未来候选药物的发现提供指导。
期刊介绍:
Expert Opinion on Drug Discovery (ISSN 1746-0441 [print], 1746-045X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.
The Editors welcome:
Reviews covering chemoinformatics; bioinformatics; assay development; novel screening technologies; in vitro/in vivo models; structure-based drug design; systems biology
Drug Case Histories examining the steps involved in the preclinical and clinical development of a particular drug
The audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and other closely related professionals looking to enhance the success of their drug candidates through optimisation at the preclinical level.